HealthLeaders Media January 31, 2019
Steven Porter

The proposal would end safe-harbor protections for the rebates drug manufacturers pay to PBMs and add safe-harbor protections for drug discounts offered directly to patients.

In a highly anticipated move to curb prescription drug prices, the Trump administration announced plans Thursday to effectively kill the rebates drug makers pay to pharmacy benefit managers.

The idea is to pass savings along to patients by increasing transparency, encouraging discounts given directly to consumers rather than middlemen, and prohibiting a compensation system that incentivizes annual price hikes, according to Health and Human Services.

“This proposal has the potential to be the most significant change in how Americans’ drugs are priced at the pharmacy counter, ever, and finally ease the burden of the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Govt Agencies, HHS, Pharma, Regulations
Pfizer shifts creative to Publicis in latest marketing move
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Understanding the politics of drug pricing in the United States
FDA approves Akebia anemia pill, two years after rejection

Share This Article